JP2018510636A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510636A5 JP2018510636A5 JP2017549507A JP2017549507A JP2018510636A5 JP 2018510636 A5 JP2018510636 A5 JP 2018510636A5 JP 2017549507 A JP2017549507 A JP 2017549507A JP 2017549507 A JP2017549507 A JP 2017549507A JP 2018510636 A5 JP2018510636 A5 JP 2018510636A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- cdr3
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 100
- 102000036639 antigens Human genes 0.000 claims description 100
- 108091007433 antigens Proteins 0.000 claims description 100
- 239000012634 fragment Substances 0.000 claims description 56
- 101000914326 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 6 Proteins 0.000 claims description 30
- 102100025473 Carcinoembryonic antigen-related cell adhesion molecule 6 Human genes 0.000 claims description 16
- 102000046810 human CEACAM6 Human genes 0.000 claims description 14
- 241000282567 Macaca fascicularis Species 0.000 claims description 10
- 229940125644 antibody drug Drugs 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 210000004027 cell Anatomy 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 150000007523 nucleic acids Chemical group 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 108010062802 CD66 antigens Proteins 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 125000000539 amino acid group Chemical group 0.000 claims description 4
- 230000035772 mutation Effects 0.000 claims description 4
- 230000003053 immunization Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 102100024533 Carcinoembryonic antigen-related cell adhesion molecule 1 Human genes 0.000 claims description 2
- 102220470708 Carcinoembryonic antigen-related cell adhesion molecule 6_I63F_mutation Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 101000914337 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 3 Proteins 0.000 claims description 2
- 101000914324 Homo sapiens Carcinoembryonic antigen-related cell adhesion molecule 5 Proteins 0.000 claims description 2
- 102100037850 Interferon gamma Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 229940039227 diagnostic agent Drugs 0.000 claims description 2
- 239000000032 diagnostic agent Substances 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 102000055639 human CEACAM3 Human genes 0.000 claims description 2
- 102000047627 human CEACAM5 Human genes 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 210000001236 prokaryotic cell Anatomy 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102220193249 rs1057516144 Human genes 0.000 claims description 2
- 230000028327 secretion Effects 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15160292 | 2015-03-23 | ||
| EP15160292.7 | 2015-03-23 | ||
| PCT/EP2016/056104 WO2016150899A2 (en) | 2015-03-23 | 2016-03-21 | Anti-ceacam6 antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020212437A Division JP7185379B2 (ja) | 2015-03-23 | 2020-12-22 | 抗ｃｅａｃａｍ６抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510636A JP2018510636A (ja) | 2018-04-19 |
| JP2018510636A5 true JP2018510636A5 (enExample) | 2019-02-21 |
| JP6815329B2 JP6815329B2 (ja) | 2021-01-20 |
Family
ID=52692556
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017549507A Active JP6815329B2 (ja) | 2015-03-23 | 2016-03-21 | 抗ｃｅａｃａｍ６抗体およびその使用 |
| JP2020212437A Active JP7185379B2 (ja) | 2015-03-23 | 2020-12-22 | 抗ｃｅａｃａｍ６抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020212437A Active JP7185379B2 (ja) | 2015-03-23 | 2020-12-22 | 抗ｃｅａｃａｍ６抗体およびその使用 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10584167B2 (enExample) |
| EP (2) | EP3628688A1 (enExample) |
| JP (2) | JP6815329B2 (enExample) |
| KR (1) | KR102749339B1 (enExample) |
| CN (1) | CN107743495B (enExample) |
| AR (1) | AR104047A1 (enExample) |
| AU (1) | AU2016236270B2 (enExample) |
| BR (1) | BR112017020373A2 (enExample) |
| CA (1) | CA2980390A1 (enExample) |
| CY (1) | CY1122627T1 (enExample) |
| DK (1) | DK3274370T3 (enExample) |
| ES (1) | ES2768784T3 (enExample) |
| HR (1) | HRP20192280T1 (enExample) |
| HU (1) | HUE048111T2 (enExample) |
| IL (1) | IL254534B (enExample) |
| LT (1) | LT3274370T (enExample) |
| MX (1) | MX376973B (enExample) |
| PE (1) | PE20171790A1 (enExample) |
| PL (1) | PL3274370T3 (enExample) |
| PT (1) | PT3274370T (enExample) |
| RS (1) | RS59878B1 (enExample) |
| RU (1) | RU2739163C2 (enExample) |
| SG (1) | SG11201707800QA (enExample) |
| SI (1) | SI3274370T1 (enExample) |
| TW (1) | TWI719969B (enExample) |
| WO (1) | WO2016150899A2 (enExample) |
| ZA (1) | ZA201707138B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE048111T2 (hu) * | 2015-03-23 | 2020-05-28 | Bayer Pharma AG | Anti-CEACAM6 ellenanyagok és alkalmazásuk |
| KR102590454B1 (ko) | 2016-07-07 | 2023-10-17 | 더 보드 어브 트러스티스 어브 더 리랜드 스탠포드 주니어 유니버시티 | 항체-애쥬번트 접합체 |
| EP3523333B1 (en) | 2016-10-10 | 2023-12-13 | Singapore Health Services Pte Ltd | Anti-ceacam6 antibodies and methods of use |
| CN110382533B (zh) * | 2016-11-14 | 2023-09-22 | 锦湖Ht株式会社 | 特异性结合CD66c的抗体及其用途 |
| WO2018128486A1 (ko) * | 2017-01-05 | 2018-07-12 | 한국생명공학연구원 | Ceacam6에 특이적으로 결합하는 항-ceacam6 키메릭 항원 수용체 |
| CA3092434A1 (en) * | 2017-02-27 | 2018-08-30 | Caerus Therapeutics, Inc. | Compositions of a novel anti-human ceacam6 antibody and uses thereof |
| KR20190140943A (ko) * | 2017-04-24 | 2019-12-20 | 메모리얼 슬로안 케터링 캔서 센터 | 항-cd33 항체 제제 |
| WO2018217459A2 (en) * | 2017-05-23 | 2018-11-29 | Academia Sinica | Conditional internalization of pegylated agents by pretargeting bi-specific peg-binding antibodies for diagnosis and therapy |
| PT3587445T (pt) * | 2017-08-10 | 2024-03-14 | Grifols Diagnostic Solutions Inc | Um marcador de oligomerização compreendendo uma região fc de imunoglobulina e um domínio poli-his |
| KR102134954B1 (ko) | 2018-01-08 | 2020-07-16 | 충북대학교 산학협력단 | CEACAM6 발현 억제를 위한 siRNA 및 이를 포함하는 선암 치료제 |
| CA3091181A1 (en) * | 2018-02-13 | 2019-08-22 | Precision Biologics, Inc. | Methods and compositions for targeting treg cells |
| AU2019233576A1 (en) * | 2018-03-13 | 2020-09-17 | Cancer Research Technology Limited | Anti-CD25 for tumour specific cell depletion |
| KR102373502B1 (ko) * | 2018-05-14 | 2022-03-11 | 주식회사 금호에이치티 | 골수유래억제세포 관련 질환의 예방 및 치료 용도 |
| MX2020012567A (es) | 2018-05-23 | 2021-01-29 | Beigene Ltd | Anticuerpos anti-ox40 y metodos de uso. |
| EP3802599B1 (en) * | 2018-06-03 | 2023-12-20 | LamKap Bio beta AG | Bispecific antibodies against ceacam5 and cd47 |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| US20220010017A1 (en) * | 2018-11-14 | 2022-01-13 | Bayer Aktiengesellschaft | Pharmaceutical combination of anti-ceacam6 and either anti-pd-1 or anti-pd-l1 antibodies for the treatment of cancer |
| EP3897844B1 (en) | 2018-12-19 | 2023-11-15 | Deutsches Krebsforschungszentrum | Pharmaceutical combination of anti ceacam6 and tim3 antibodies |
| JP2022525594A (ja) | 2019-03-15 | 2022-05-18 | ボルト バイオセラピューティクス、インコーポレーテッド | Ｈｅｒ２を標的とする免疫結合体 |
| US20220235142A1 (en) * | 2019-06-04 | 2022-07-28 | Shanghai GenBase Biotechnology Co., Ltd. | Anti-ceacam5 monoclonal antibody, preparation method thereof and use thereof |
| US20220401374A1 (en) * | 2019-09-13 | 2022-12-22 | Purdue Research Foundation | Compositions and methods for cancer treatment by enhancing antitumor immunity using tannic acid-based nanocapsules |
| US20230115540A1 (en) * | 2020-03-06 | 2023-04-13 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Tumor targeted fluorescence guidance for intraoperative margin assessment |
| CN111533808B (zh) * | 2020-03-10 | 2021-02-09 | 南京医科大学 | 一种可自分泌TLR4 scFv且靶向cMet的嵌合抗原受体修饰的T细胞及其应用 |
| CN113637073B (zh) * | 2020-05-11 | 2024-04-12 | 上海赛比曼生物科技有限公司 | Bcma抗体及其制备和应用 |
| CN112457402B (zh) * | 2020-10-21 | 2022-08-30 | 北京纽安博生物技术有限公司 | 抗ceacam6单域抗体、人源化单域抗体及其融合蛋白和应用 |
| WO2022116079A1 (zh) * | 2020-12-03 | 2022-06-09 | 上海吉倍生物技术有限公司 | 一种抗ceacam5的人源化抗体及其制备方法和用途 |
| CA3204204A1 (en) * | 2020-12-11 | 2022-06-16 | Materia Therapeutics Inc. | Cancer treatment using bosentan in combination with a checkpoint inhibitor |
| US20240052031A1 (en) * | 2020-12-18 | 2024-02-15 | Bioardis, Llc | Cea6 binding molecules and uses thereof |
| CN112521509B (zh) * | 2020-12-23 | 2022-07-08 | 姚雪英 | 一种抗ceacam5人源化抗体、其缀合物及其用途 |
| WO2023031366A1 (en) | 2021-09-02 | 2023-03-09 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Anti-cecam6 antibodies with reduced side-effects |
| KR20250024741A (ko) | 2022-03-23 | 2025-02-19 | 시나픽스 비.브이. | 암배아성 항원을 발현하는 종양을 표적화하기 위한 항체-컨쥬게이트 |
| CN116196415B (zh) * | 2022-12-07 | 2023-08-01 | 浙江省肿瘤医院 | 用于增敏pd-1抗体的混合制剂及其使用方法 |
| EP4720123A1 (en) * | 2023-05-25 | 2026-04-08 | Biolegend, Inc. | Ceacam6 binding antibodies and antigen-binding fragments thereof |
| EP4626931A1 (en) * | 2023-09-17 | 2025-10-08 | Ji Yan Biomedical Co., Ltd | Recombinant antibodies and uses thereof |
| WO2025237329A1 (en) * | 2024-05-15 | 2025-11-20 | Nona Biosciences (Suzhou) Co., Ltd. | Ceacam6-binding protein |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| CA2026147C (en) | 1989-10-25 | 2006-02-07 | Ravi J. Chari | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| ATE255131T1 (de) | 1991-06-14 | 2003-12-15 | Genentech Inc | Humanisierter heregulin antikörper |
| US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
| US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
| ATE219517T1 (de) | 1995-08-18 | 2002-07-15 | Morphosys Ag | Protein-/(poly)peptidbibliotheken |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| CA2293829C (en) | 1997-06-24 | 2011-06-14 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
| DE69840412D1 (de) | 1997-10-31 | 2009-02-12 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
| ES2375931T3 (es) | 1997-12-05 | 2012-03-07 | The Scripps Research Institute | Humanización de anticuerpo murino. |
| IL138608A0 (en) | 1998-04-02 | 2001-10-31 | Genentech Inc | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| NZ581474A (en) | 2001-08-03 | 2011-04-29 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| EP1944320A1 (en) | 2002-12-16 | 2008-07-16 | Genentech, Inc. | Immunoglobulin variants and uses thereof |
| PT1692182E (pt) | 2003-11-05 | 2010-05-13 | Roche Glycart Ag | Anticorpos de cd20 com uma afinidade de ligação acrescida ao receptor fc e uma função efectora acrescida |
| EP3434275A1 (en) | 2003-11-06 | 2019-01-30 | Seattle Genetics, Inc. | Assay for cancer cells based on the use of auristatin conjugates with antibodies |
| CA2561686C (en) | 2004-03-31 | 2014-12-02 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| ES2545609T3 (es) | 2008-08-25 | 2015-09-14 | Amplimmune, Inc. | Composiciones de antagonistas de PD-1 y métodos de uso |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| CA2774260C (en) * | 2009-09-16 | 2018-10-09 | Immunomedics, Inc. | Class i anti-cea antibodies and uses thereof |
| NO2504364T3 (enExample) | 2009-11-24 | 2018-01-06 | ||
| US8404812B2 (en) * | 2010-02-26 | 2013-03-26 | Dinona Inc. | Epitope of CD66C specific to lung adenocarcinoma and antibody recognizing the same |
| CA2803391C (en) | 2010-06-22 | 2021-11-09 | Neogenix Oncology, Inc. | Npc1 antibodies that bind a muc5ac epitope |
| CA2813133C (en) * | 2010-10-01 | 2023-10-31 | National Research Council Of Canada | Anti-ceacam6 antibodies and uses thereof |
| EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
| US9624298B2 (en) | 2011-11-28 | 2017-04-18 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| RU2493166C1 (ru) * | 2012-04-09 | 2013-09-20 | Общество с ограниченной ответственностью "Технофарма" | Наноантитело, специфически связывающее белок сеа, способ его использования для детекции этого белка |
| AU2013263076B2 (en) | 2012-05-15 | 2017-08-31 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting PD-1/PD-L1 signaling |
| US10131712B2 (en) | 2012-08-14 | 2018-11-20 | Ibc Pharmaceuticals, Inc. | Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors |
| LT3702373T (lt) | 2013-09-13 | 2022-11-10 | Beigene Switzerland Gmbh | Anti-pd1 antikūnai ir jų naudojimas terapijai ir diagnostikai |
| AU2015210750B2 (en) | 2014-01-31 | 2020-08-20 | Children's Medical Center Corporation | Antibody molecules to TIM-3 and uses thereof |
| HUE048111T2 (hu) * | 2015-03-23 | 2020-05-28 | Bayer Pharma AG | Anti-CEACAM6 ellenanyagok és alkalmazásuk |
| EP3277321B1 (en) | 2015-04-01 | 2024-08-14 | AnaptysBio, Inc. | Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3) |
| RS62736B1 (sr) | 2016-04-12 | 2022-01-31 | Symphogen As | Anti-tim-3 antitela i kompozicije |
| MX389710B (es) | 2016-05-27 | 2025-03-20 | Agenus Inc | Anticuerpos anti proteina inmunoglobulina de linfocitos t y dominio de mucina 3 (tim-3) y métodos para usarlos. |
| SG11201900026TA (en) | 2016-07-14 | 2019-01-30 | Bristol Myers Squibb Co | Antibodies against tim3 and uses thereof |
| JOP20190013A1 (ar) | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
| CN110382533B (zh) | 2016-11-14 | 2023-09-22 | 锦湖Ht株式会社 | 特异性结合CD66c的抗体及其用途 |
| JP7118073B2 (ja) | 2017-01-09 | 2022-08-15 | テサロ， インコーポレイテッド | 抗ｔｉｍ－３抗体を用いてがんを処置する方法 |
-
2016
- 2016-03-21 HU HUE16713784A patent/HUE048111T2/hu unknown
- 2016-03-21 MX MX2017012278A patent/MX376973B/es active IP Right Grant
- 2016-03-21 PE PE2017001579A patent/PE20171790A1/es unknown
- 2016-03-21 LT LTEP16713784.3T patent/LT3274370T/lt unknown
- 2016-03-21 RU RU2017137010A patent/RU2739163C2/ru active
- 2016-03-21 CN CN201680024895.XA patent/CN107743495B/zh active Active
- 2016-03-21 AU AU2016236270A patent/AU2016236270B2/en active Active
- 2016-03-21 PL PL16713784T patent/PL3274370T3/pl unknown
- 2016-03-21 HR HRP20192280TT patent/HRP20192280T1/hr unknown
- 2016-03-21 EP EP19202632.6A patent/EP3628688A1/en active Pending
- 2016-03-21 RS RS20200132A patent/RS59878B1/sr unknown
- 2016-03-21 WO PCT/EP2016/056104 patent/WO2016150899A2/en not_active Ceased
- 2016-03-21 ES ES16713784T patent/ES2768784T3/es active Active
- 2016-03-21 PT PT167137843T patent/PT3274370T/pt unknown
- 2016-03-21 SG SG11201707800QA patent/SG11201707800QA/en unknown
- 2016-03-21 DK DK16713784.3T patent/DK3274370T3/da active
- 2016-03-21 BR BR112017020373-1A patent/BR112017020373A2/pt not_active IP Right Cessation
- 2016-03-21 CA CA2980390A patent/CA2980390A1/en active Pending
- 2016-03-21 JP JP2017549507A patent/JP6815329B2/ja active Active
- 2016-03-21 SI SI201630585T patent/SI3274370T1/sl unknown
- 2016-03-21 EP EP16713784.3A patent/EP3274370B1/en active Active
- 2016-03-21 KR KR1020177029946A patent/KR102749339B1/ko active Active
- 2016-03-21 TW TW105108621A patent/TWI719969B/zh active
- 2016-03-21 US US15/561,013 patent/US10584167B2/en active Active
- 2016-03-22 AR ARP160100772A patent/AR104047A1/es not_active Application Discontinuation
-
2017
- 2017-09-17 IL IL254534A patent/IL254534B/en unknown
- 2017-10-20 ZA ZA2017/07138A patent/ZA201707138B/en unknown
-
2020
- 2020-01-29 US US16/776,326 patent/US11773164B2/en active Active
- 2020-01-29 US US16/776,329 patent/US11866495B2/en active Active
- 2020-02-13 CY CY20201100133T patent/CY1122627T1/el unknown
- 2020-12-22 JP JP2020212437A patent/JP7185379B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2017137010A (ru) | Анти-сеасам6 антитела и их применения | |
| JP7254699B2 (ja) | 抗ｂｃｍａ重鎖のみ抗体 | |
| JP2021533726A5 (enExample) | ||
| JP2021515565A5 (enExample) | ||
| JP2021516973A5 (enExample) | ||
| JP2021516974A5 (enExample) | ||
| JP7257971B6 (ja) | 抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用 | |
| JP2021515568A5 (enExample) | ||
| RU2008129111A (ru) | Антитела к ox40l и способы их применения | |
| JP2022533538A5 (enExample) | ||
| JP2015163068A5 (enExample) | ||
| JP2021514973A5 (enExample) | ||
| KR20160127825A (ko) | 항-mcam 항체 및 관련된 사용 방법 | |
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| KR20210099027A (ko) | 항-cd40 항체, 이의 항원-결합 단편 및 약학적 용도 | |
| RU2012122203A (ru) | Композиции и способы для лечения восполительных нарушений | |
| RU2011151287A (ru) | АНТИ Notch-1 АНТИТЕЛА | |
| JP2020533965A5 (enExample) | ||
| WO2023040940A1 (zh) | Pvrig/tigit结合蛋白联合免疫检查点抑制剂用于治疗癌症 | |
| US12173081B2 (en) | CD19/CD38 multispecific antibodies | |
| JP2020531003A5 (enExample) | ||
| JP2023517794A5 (enExample) | ||
| RU2020128108A (ru) | Антитело против cd25 для опухоль-специфической клеточной деплеции | |
| AU2021231712A1 (en) | Anti-CD19 antibodies and methods of using and making thereof | |
| RU2779128C2 (ru) | Антитело к cd40, его антигенсвязывающий фрагмент и его медицинское применение |